The massive insider buying cluster — led by a director ($5M) and a major institutional holder ($10M) — signals strong conviction at current levels. Traders should watch for potential upcoming catalysts (pipeline data, partnership, or earnings) that may have motivated this coordinated buying. The $16/share level now serves as a key support floor given insider cost basis.
Price Chart
Executive Summary
A cluster of insider open-market purchases totaling $5.14M occurred at BlossomHill Therapeutics on August 10, 2026. Director Chen Bihua led with a $5M buy, alongside smaller purchases by the CFO, General Counsel, and another director. This follows a $10M purchase by OrbiMed Advisors on the same day, creating a combined $15.1M insider buying cluster at $16/share, representing ~3% of the company's $500M market cap — a highly material signal of insider conviction.
Key Financial Metrics
Key Facts
- Four insiders made open-market purchases totaling $5.14M on August 10, 2026, all at $16/share.
- Director Chen Bihua purchased $5M worth of shares (312.5K shares), the largest individual buy.
- CFO Jason Keyes, General Counsel Vincent Liptak, and Director John Schmid also bought shares.
- OrbiMed Advisors, a director, separately purchased $10M in shares on the same day, bringing the cluster total to $15.1M.
- The combined insider purchases represent approximately 3% of BlossomHill's $500M market cap.
- All purchases were open-market transactions, not option exercises or grants.
Financial Impact
Total insider open-market purchases of $15.1M (including OrbiMed's $10M buy) at $16/share, representing ~3% of the $500M market cap.
Risk Factors
- Insider purchases could be pre-arranged under 10b5-1 plans, though the cluster nature and size suggest conviction.
- Biotech stocks are binary — a negative pipeline readout could erase the insider support level.
- The $15.1M cluster is large relative to market cap but represents a small fraction of OrbiMed's total AUM.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BLSM-1786608155032 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | Press Release | $21.34 $16.39 | ▲ +23.20% | ▲ +23.16% | $16.39 (+23.20%) |
Sep 18, 2026 5w ago | 8-K | $25.74 $13.94 | ▲ +45.84% | ▲ +46.05% | $16.39 (+36.32%) |
Sep 18, 2026 5w ago | Press Release | $25.74 $13.94 | ▼ −45.84% | ▼ −46.05% | $16.39 (−36.32%) |
Sep 15, 2026 5w ago | 8-K | $22.17 $15.48 | ▼ −30.18% | ▼ −33.15% | $16.39 (−26.07%) |
Aug 12, 2026 10w ago | Insider Cluster | $16.35 $20.86 | ▲ +27.58% | ▲ +29.33% | $16.39 (+0.24%) |
Aug 10, 2026 11w ago | Insider Cluster | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $16.39 (−0.79%) |
Aug 10, 2026 11w ago | 8-K | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $16.39 (−0.79%) |
Aug 7, 2026 11w ago | 424B4 | $15.99 $22.93 | ▲ +43.40% | ▲ +44.32% | $16.39 (+2.50%) |
Aug 7, 2026 11w ago | EFFECT | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $16.39 (+2.44%) |
Aug 6, 2026 11w ago | 3 | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $16.39 (+2.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers